Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT06662786
- Locations
- 🇧🇷
Fundacao Doutor Amaral Carvalho, Jau, Brazil
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, China
🇩🇪Universitatsklinikum Ulm, Ulm, Germany
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
- Conditions
- Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Radiologic Imaging Procedure
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT06654037
- Locations
- 🇺🇸
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
- Conditions
- Colon CancerRectal Cancer
- Interventions
- Drug: Ultrafractionated RT and CGA Guided systemic treatment.Other: data prospectively collectedRadiation: Ultrafractionated Radiotherapy
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 124
- Registration Number
- NCT06652412
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 68
- Registration Number
- NCT06648525
- Locations
- 🇨🇳
Harbin Medical University, Harbin, Heilongjiang, China
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06632717
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630, Irvine, California, United States
🇺🇸UCLA - Santa Monica /ID# 270024, Santa Monica, California, United States
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Conditions
- Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
🇺🇸City of Hope-Duarte, Duarte, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 540
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.